Literature DB >> 1659613

Studies on inhibitors of skin tumor promotion, IX. Neolignans from Magnolia officinalis.

T Konoshima1, M Kozuka, H Tokuda, H Nishino, A Iwashima, M Haruna, K Ito, M Tanabe.   

Abstract

Three neolignans, known as magnolol [1], honokiol [2] and the new monoterpenylmagnolol [3], were isolated from the bark of Magnolia officinalis as inhibitors of Epstein-Barr virus early antigen (EBV-EA) activation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA). The structure of 3 was determined from 2D nmr spectral data and difference nOe experiments. The MeOH extract of this plant and magnolol exhibited remarkable inhibitory effects on mouse skin tumor promotion in an in vivo two stage carcinogenesis test. This investigation indicates that these neolignans and the extract might be valuable antitumor promoters.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1659613     DOI: 10.1021/np50075a010

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  24 in total

1.  In vitro growth inhibition of human cancer cells by novel honokiol analogs.

Authors:  Jyh Ming Lin; A S Prakasha Gowda; Arun K Sharma; Shantu Amin
Journal:  Bioorg Med Chem       Date:  2012-04-03       Impact factor: 3.641

2.  Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.

Authors:  Rebecca J Leeman-Neill; Quan Cai; Sonali C Joyce; Sufi M Thomas; Neil E Bhola; Daniel B Neill; Jack L Arbiser; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2010-04-13       Impact factor: 12.531

3.  Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis.

Authors:  Kenji Ishitsuka; Teru Hideshima; Makoto Hamasaki; Noopur Raje; Shaji Kumar; Hiromasa Hideshima; Norihiko Shiraishi; Hiroshi Yasui; Aldo M Roccaro; Paul Richardson; Klaus Podar; Steven Le Gouill; Dharminder Chauhan; Kazuo Tamura; Jack Arbiser; Kenneth C Anderson
Journal:  Blood       Date:  2005-05-03       Impact factor: 22.113

Review 4.  Honokiol, a multifunctional antiangiogenic and antitumor agent.

Authors:  Levi E Fried; Jack L Arbiser
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

5.  Synergistic antitumor effects of liposomal honokiol combined with cisplatin in colon cancer models.

Authors:  Niang Cheng; Tian Xia; Ying Han; Qing Jun He; Rong Zhao; Jun Rong Ma
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

6.  The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways.

Authors:  Pallavi Banerjee; Aninda Basu; Jack L Arbiser; Soumitro Pal
Journal:  Cancer Lett       Date:  2013-06-07       Impact factor: 8.679

7.  The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis.

Authors:  Shruti M Raja; Shuzhen Chen; Ping Yue; Timothy M Acker; Benjamin Lefkove; Jack L Arbiser; Fadlo R Khuri; Shi-Yong Sun
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

8.  Effector mechanism of magnolol-induced apoptosis in human lung squamous carcinoma CH27 cells.

Authors:  Shu-Er Yang; Ming-Tsuen Hsieh; Tung-Hu Tsai; Shih-Lan Hsu
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

9.  Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis.

Authors:  Arumugam Nagalingam; Jack L Arbiser; Michael Y Bonner; Neeraj K Saxena; Dipali Sharma
Journal:  Breast Cancer Res       Date:  2012-02-21       Impact factor: 6.466

10.  Magnolol, a natural compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via the mitochondrial and PI3K/Akt signaling pathways.

Authors:  Azhar Rasul; Bo Yu; Muhammad Khan; Kun Zhang; Furhan Iqbal; Tonghui Ma; Hong Yang
Journal:  Int J Oncol       Date:  2011-11-30       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.